Wells Fargo Lowers Nuvalent, Inc. Rating to Hold

Wells Fargo downgraded Nuvalent to 'hold' with a $124 target.

Written by Trueearnings · Published Jun 14, 2026, 2:01 AM EDT · Updated Jun 14, 2026, 8:00 PM EDT

Key Points

Wells Fargo downgraded Nuvalent, Inc. to 'hold' with a $124 price target on June 9, 2026.
Nuvalent's stock traded at $123.25, with a market cap of $9.75 billion and a 52-week high of $123.62.
Insider trades included sales by the CEO and Chief Development Officer, with analysts setting a consensus 'hold' rating.

Wells Fargo has downgraded its rating on Nuvalent, Inc. (NasdaqGS: NUVL) to 'hold' with a price target of $124. This change, announced on June 9, 2026, reflects a cautious stance by analyst Eva Fortea Verdejo.

Other Institutional Activity in Nuvalent

Deerfield Management Company maintained its position in Nuvalent with 17,248,450 shares valued at approximately $1.77 billion. FMR LLC reduced its holdings by 1,577,925 shares, ending with 9,274,959 shares worth about $950.2 million. Paradigm Biocapital Advisors LP increased its stake by 55,000 shares, holding 5,324,433 shares valued at $545.5 million. BlackRock, Inc. added 19,524 shares, resulting in 4,824,785 shares worth $494.3 million. JPMorgan Chase & Co significantly boosted its position by 883,098 shares, holding 3,088,349 shares valued at $298.7 million.

Nuvalent, Inc. Stock Snapshot

Shares of Nuvalent, Inc. traded near $123.25, just shy of its 52-week high of $123.62. The company has a market cap of about $9.75 billion. Although Nuvalent isn't profitable, it has a high current ratio of 16.14 and a quick ratio of 15.89, indicating strong liquidity. The stock's 50-day moving average is $104.10, and its 200-day moving average is $98.73.

Insider Buying and Selling at Nuvalent, Inc.

On June 9, 2026, Darlene Noci, Nuvalent's Chief Development Officer, sold 20,000 shares at an average price of $122.81 under a planned transaction. On the same day, she also bought 20,000 shares at $9.59. On June 8, CEO Dr. James R. Porter sold 30,000 shares at $88.53 in a planned sale and bought the same amount at $18.93.

Analysts Set New Price Targets

Several firms, including TD Cowen, Barclays, UBS, and Guggenheim, downgraded Nuvalent to 'hold' with a price target of $124 on June 10, 2026. The consensus among 16 analysts is a 'hold' rating, with an average target price of $128.13.

About Nuvalent, Inc.

Nuvalent, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It focuses on developing therapies for cancer patients. The company's lead products include Zidesamtinib and Neladalkib, which are in various phases of clinical trials. Nuvalent collaborates with Guardant Health to develop companion diagnostic therapies. The company was founded in 2017 and is led by CEO Dr. James R. Porter.

Bottom Line

Wells Fargo's downgrade of Nuvalent to 'hold' reflects a more cautious outlook on the company's prospects. Investors keep a close eye on such analyst ratings as they can influence stock performance. Remember, these ratings are based on past data and do not necessarily indicate future performance.